---
title: Chinese Cancer Biologics (Global Competitors)
type: technology
url: "https://www.envisioning.com/research/helix/china__chinese-cancer-biologics-global-competitors"
hub: helix
summary: "BeiGene's Brukinsa became the first Chinese cancer therapy approved by the FDA, now in 65+ countries with $2B+ annual sales — while Akeso's ivonescimab challenges Keytruda, the world's..."
---

# Chinese Cancer Biologics (Global Competitors)

BeiGene's Brukinsa became the first Chinese cancer therapy approved by the FDA, now in 65+ countries with $2B+ annual sales — while Akeso's ivonescimab challenges Keytruda, the world's...
- Technology Readiness Level: 8/9
- Impact: 4/5
- Investment: 5/5
China's biotech industry went from 'me too' (copying existing drugs) to 'first in class' (inventing new ones) in 14 years. Betta Pharma's Conmana (2011) was a domestic-market variation. BeiGene's Brukinsa (2019) went global. Now Akeso's ivonescimab — a bispecific antibody with a novel mechanism — is challenging Keytruda ($25B annual sales) in head-to-head trials.

Legend Biotech's Carvykti, a CAR-T cell therapy developed in Xi'an and commercialized globally with Johnson & Johnson, has treated over 5,000 cancer patients in 36+ countries. The $5B licensing deal between Akeso and Summit Therapeutics for ivonescimab's global rights shows Western pharma betting on Chinese drug innovation.

The structural shift: China's biotech companies are no longer licensing Western drugs for the domestic market. They're licensing Chinese drugs to Western companies for global markets. The direction of technology transfer has reversed.

---
Source: Envisioning — Technology Research Institute (https://www.envisioning.com/research/helix/china__chinese-cancer-biologics-global-competitors)